Cadonilimab Phase III Trial Begins for Colon Cancer Treatment

Akeso, Inc. has initiated a Phase III clinical study (COMPASSION-40) for cadonilimab, a bispecific antibody, in treating resectable MSI-H/dMMR colon cancer. The trial, which has dosed its first patient, aims to evaluate the drug as a monotherapy, building on prior promising Phase II data. This development marks a significant step in potentially expanding treatment options for this specific type of colon cancer.